A biotechnology company engaged in the development, production and distribution of innovative drugs created by genetic engineering
Founded in 1980, Amgen Is a leader in the biotechnology industry and one of the first companies to unlock the potential of a new generation of effective and safe drugs and fundamentally new approaches to the treatment of serious diseases.
Amgen drugs have changed everyday medical practice, helping millions of people around the world to deal with severe oncological, hematological and nephrological diseases, rheumatoid arthritis and other serious pathologies. The extensive portfolio of drugs being developed to date (more than 50 new molecules at different stages of development and research) confirms the company’s commitment to using scientific advances to improve people’s lives.
Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen’s discovery research efforts — and a major contributor to the development of Amgen’s deep and broad pipeline of potential new medicines. Amgen’s “biology first” approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.
The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.
Building on advances in recombinant DNA and molecular biology, Amgen is counted among the early pioneers of biotechnology. Since 1980, Amgen scientists have been at work developing novel therapies for patients with serious illnesses. Our scientists have characterized key biologic processes that have led to the development of innovative, first-in-class therapies. We have helped shape the scientific world’s understanding of certain disease processes, and we have engineered new types of therapeutic platforms. As a company, we could not have accomplished what we have were it not for our deep commitment to building a culture that embraces science and innovation — a culture that continues to shape who we are today.
The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated nearly $300 million in grants to local, regional and international nonprofit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars, Amgen Biotech Experience and Amgen Teach. For more information, visit www.AmgenInspires.com.
Like 35 years ago, Amgen remains true to its mission:
"Serve patients suffering from severe diseases by developing innovative medicines to meet medical needs."
![](https://landing.gxpnews.net/wp-content/uploads/2021/04/amgen-logo-01-1.png)
Amgen LLC, Russia, Moscow, 123112
Presnenskaya naberezhnaya 8, bld.1, fl.7
tel: +7(495)745-0478/79; fax: +7 (499) 995-1965
For information about our pipeline and therapies,
visit our official website